GEMMs as preclinical models for testing pancreatic cancer therapies
Pancreatic ductal adenocarcinoma is the most common form of pancreatic tumour, with a very limited survival rate and currently no available disease-modifying treatments. Despite recent advances in the production of genetically engineered mouse models (GEMMs), the development of new therapies for pan...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Company of Biologists
2015-10-01
|
| Series: | Disease Models & Mechanisms |
| Subjects: | |
| Online Access: | http://dmm.biologists.org/content/8/10/1185 |
| _version_ | 1818695112551563264 |
|---|---|
| author | Aarthi Gopinathan Jennifer P. Morton Duncan I. Jodrell Owen J. Sansom |
| author_facet | Aarthi Gopinathan Jennifer P. Morton Duncan I. Jodrell Owen J. Sansom |
| author_sort | Aarthi Gopinathan |
| collection | DOAJ |
| description | Pancreatic ductal adenocarcinoma is the most common form of pancreatic tumour, with a very limited survival rate and currently no available disease-modifying treatments. Despite recent advances in the production of genetically engineered mouse models (GEMMs), the development of new therapies for pancreatic cancer is still hampered by a lack of reliable and predictive preclinical animal models for this disease. Preclinical models are vitally important for assessing therapies in the first stages of the drug development pipeline, prior to their transition to the clinical arena. GEMMs carry mutations in genes that are associated with specific human diseases and they can thus accurately mimic the genetic, phenotypic and physiological aspects of human pathologies. Here, we discuss different GEMMs of human pancreatic cancer, with a focus on the Lox-Stop-Lox (LSL)-KrasG12D; LSL-Trp53R172H; Pdx1-cre (KPC) model, one of the most widely used preclinical models for this disease. We describe its application in preclinical research, highlighting its advantages and disadvantages, its potential for predicting clinical outcomes in humans and the factors that can affect such outcomes, and, finally, future developments that could advance the discovery of new therapies for pancreatic cancer. |
| first_indexed | 2024-12-17T13:40:18Z |
| format | Article |
| id | doaj.art-5e6bdc5d49834fd9899584727434905b |
| institution | Directory Open Access Journal |
| issn | 1754-8411 1754-8403 |
| language | English |
| last_indexed | 2024-12-17T13:40:18Z |
| publishDate | 2015-10-01 |
| publisher | The Company of Biologists |
| record_format | Article |
| series | Disease Models & Mechanisms |
| spelling | doaj.art-5e6bdc5d49834fd9899584727434905b2022-12-21T21:46:18ZengThe Company of BiologistsDisease Models & Mechanisms1754-84111754-84032015-10-018101185120010.1242/dmm.021055021055GEMMs as preclinical models for testing pancreatic cancer therapiesAarthi Gopinathan0Jennifer P. Morton1Duncan I. Jodrell2Owen J. Sansom3 Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK Cancer Research UK Beatson Institute, Glasgow, G61 1BD, UK Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK Cancer Research UK Beatson Institute, Glasgow, G61 1BD, UK Pancreatic ductal adenocarcinoma is the most common form of pancreatic tumour, with a very limited survival rate and currently no available disease-modifying treatments. Despite recent advances in the production of genetically engineered mouse models (GEMMs), the development of new therapies for pancreatic cancer is still hampered by a lack of reliable and predictive preclinical animal models for this disease. Preclinical models are vitally important for assessing therapies in the first stages of the drug development pipeline, prior to their transition to the clinical arena. GEMMs carry mutations in genes that are associated with specific human diseases and they can thus accurately mimic the genetic, phenotypic and physiological aspects of human pathologies. Here, we discuss different GEMMs of human pancreatic cancer, with a focus on the Lox-Stop-Lox (LSL)-KrasG12D; LSL-Trp53R172H; Pdx1-cre (KPC) model, one of the most widely used preclinical models for this disease. We describe its application in preclinical research, highlighting its advantages and disadvantages, its potential for predicting clinical outcomes in humans and the factors that can affect such outcomes, and, finally, future developments that could advance the discovery of new therapies for pancreatic cancer.http://dmm.biologists.org/content/8/10/1185Co-clinical trialsPreclinical mouse modelsPancreatic ductal adenocarcinomaPDACDrug discoveryDrug development |
| spellingShingle | Aarthi Gopinathan Jennifer P. Morton Duncan I. Jodrell Owen J. Sansom GEMMs as preclinical models for testing pancreatic cancer therapies Disease Models & Mechanisms Co-clinical trials Preclinical mouse models Pancreatic ductal adenocarcinoma PDAC Drug discovery Drug development |
| title | GEMMs as preclinical models for testing pancreatic cancer therapies |
| title_full | GEMMs as preclinical models for testing pancreatic cancer therapies |
| title_fullStr | GEMMs as preclinical models for testing pancreatic cancer therapies |
| title_full_unstemmed | GEMMs as preclinical models for testing pancreatic cancer therapies |
| title_short | GEMMs as preclinical models for testing pancreatic cancer therapies |
| title_sort | gemms as preclinical models for testing pancreatic cancer therapies |
| topic | Co-clinical trials Preclinical mouse models Pancreatic ductal adenocarcinoma PDAC Drug discovery Drug development |
| url | http://dmm.biologists.org/content/8/10/1185 |
| work_keys_str_mv | AT aarthigopinathan gemmsaspreclinicalmodelsfortestingpancreaticcancertherapies AT jenniferpmorton gemmsaspreclinicalmodelsfortestingpancreaticcancertherapies AT duncanijodrell gemmsaspreclinicalmodelsfortestingpancreaticcancertherapies AT owenjsansom gemmsaspreclinicalmodelsfortestingpancreaticcancertherapies |